Low-dose anti-IgE therapy in patients with atopic eczema with high serum IgE levels
[...]the observed outcome in our omalizumab trial might not entirely reflect drug-associated clinical changes. [...]only a very small proportion (probably between 1% and 5 % of all serum IgE molecules) in our patients was bound by omalizumab.
Gespeichert in:
| Veröffentlicht in: | Journal of allergy and clinical immunology 2007-11, Vol.120 (5), p.1223-1225 |
|---|---|
| Hauptverfasser: | , , , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 1225 |
|---|---|
| container_issue | 5 |
| container_start_page | 1223 |
| container_title | Journal of allergy and clinical immunology |
| container_volume | 120 |
| creator | Belloni, Benedetta, MD Ziai, Mahzad, MD Lim, Annick, MS Lemercier, Brigitte, BS Sbornik, Martin, MD Weidinger, Stephan, MD Andres, Christian, MD Schnopp, Christina, MD Ring, Johannes, MD Hein, Rüdiger, MD Ollert, Markus, MD Mempel, Martin, MD |
| description | [...]the observed outcome in our omalizumab trial might not entirely reflect drug-associated clinical changes. [...]only a very small proportion (probably between 1% and 5 % of all serum IgE molecules) in our patients was bound by omalizumab. |
| doi_str_mv | 10.1016/j.jaci.2007.08.060 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_68479942</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>1_s2_0_S0091674907016612</els_id><sourcerecordid>68479942</sourcerecordid><originalsourceid>FETCH-LOGICAL-c437t-ec36d842d7a30973062e810d572e6963ddfbc15baf5330ba344a783c3b91ec7a3</originalsourceid><addsrcrecordid>eNp9kc1q3DAURkVpaaZpX6CLYih0Z_dKsiULSqGEtA0MdJFkLWTpTkau_yrZCZOnj8wMBLLoSkic7-PqXEI-UigoUPG1LVpjfcEAZAF1AQJekQ0FJXNRs-o12QAomgtZqjPyLsYW0p3X6i05o1JxUSu2Idfb8SF3Y8TMDLPPr-4us3mPwUyHzA_ZZGaPwxyzBz_vMzOPk7cZ2kfszfFp7-_2WcSw9Nka7fAeu_ievNmZLuKH03lObn9e3lz8zrd_fl1d_NjmtuRyztFy4eqSOWl4GpqDYFhTcJVkKJTgzu0aS6vG7CrOoTG8LI2sueWNomhT6Jx8OfZOYfy3YJx176PFrjMDjkvUoi6lUiVL4OcXYDsuYUizaVpBKaXgXCWKHSkbxhgD7vQUfG_CQVPQq3Dd6lW4XoVrqHUSnkKfTtVL06N7jpwMJ-DbEUhi8N5j0NEmpxadD2hn7Ub___7vL-K284O3pvuLB4zP_9CRadDX68rXjYNMhYIy_gRnDaT_</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1504776339</pqid></control><display><type>article</type><title>Low-dose anti-IgE therapy in patients with atopic eczema with high serum IgE levels</title><source>MEDLINE</source><source>Elsevier ScienceDirect Journals</source><source>Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals</source><creator>Belloni, Benedetta, MD ; Ziai, Mahzad, MD ; Lim, Annick, MS ; Lemercier, Brigitte, BS ; Sbornik, Martin, MD ; Weidinger, Stephan, MD ; Andres, Christian, MD ; Schnopp, Christina, MD ; Ring, Johannes, MD ; Hein, Rüdiger, MD ; Ollert, Markus, MD ; Mempel, Martin, MD</creator><creatorcontrib>Belloni, Benedetta, MD ; Ziai, Mahzad, MD ; Lim, Annick, MS ; Lemercier, Brigitte, BS ; Sbornik, Martin, MD ; Weidinger, Stephan, MD ; Andres, Christian, MD ; Schnopp, Christina, MD ; Ring, Johannes, MD ; Hein, Rüdiger, MD ; Ollert, Markus, MD ; Mempel, Martin, MD</creatorcontrib><description>[...]the observed outcome in our omalizumab trial might not entirely reflect drug-associated clinical changes. [...]only a very small proportion (probably between 1% and 5 % of all serum IgE molecules) in our patients was bound by omalizumab.</description><identifier>ISSN: 0091-6749</identifier><identifier>EISSN: 1097-6825</identifier><identifier>DOI: 10.1016/j.jaci.2007.08.060</identifier><identifier>PMID: 17936892</identifier><language>eng</language><publisher>United States: Mosby, Inc</publisher><subject>Adult ; Allergy and Immunology ; Anti-Allergic Agents - administration & dosage ; Anti-Allergic Agents - pharmacology ; Anti-Allergic Agents - therapeutic use ; Antibodies, Anti-Idiotypic - administration & dosage ; Antibodies, Anti-Idiotypic - therapeutic use ; Antibodies, Monoclonal - administration & dosage ; Antibodies, Monoclonal - pharmacology ; Antibodies, Monoclonal - therapeutic use ; Antibodies, Monoclonal, Humanized ; Dermatitis, Atopic - drug therapy ; Drug dosages ; Eczema ; Female ; Humans ; Immunoglobulin E - blood ; Immunoglobulin E - drug effects ; Immunoglobulin E - genetics ; Immunoglobulins ; Male ; Middle Aged ; Omalizumab ; Patients ; Treatment Outcome</subject><ispartof>Journal of allergy and clinical immunology, 2007-11, Vol.120 (5), p.1223-1225</ispartof><rights>American Academy of Allergy, Asthma & Immunology</rights><rights>2007 American Academy of Allergy, Asthma & Immunology</rights><rights>Copyright Elsevier Limited Nov 2007</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c437t-ec36d842d7a30973062e810d572e6963ddfbc15baf5330ba344a783c3b91ec7a3</citedby><cites>FETCH-LOGICAL-c437t-ec36d842d7a30973062e810d572e6963ddfbc15baf5330ba344a783c3b91ec7a3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://www.sciencedirect.com/science/article/pii/S0091674907016612$$EHTML$$P50$$Gelsevier$$H</linktohtml><link.rule.ids>314,776,780,3537,27901,27902,65306</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/17936892$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Belloni, Benedetta, MD</creatorcontrib><creatorcontrib>Ziai, Mahzad, MD</creatorcontrib><creatorcontrib>Lim, Annick, MS</creatorcontrib><creatorcontrib>Lemercier, Brigitte, BS</creatorcontrib><creatorcontrib>Sbornik, Martin, MD</creatorcontrib><creatorcontrib>Weidinger, Stephan, MD</creatorcontrib><creatorcontrib>Andres, Christian, MD</creatorcontrib><creatorcontrib>Schnopp, Christina, MD</creatorcontrib><creatorcontrib>Ring, Johannes, MD</creatorcontrib><creatorcontrib>Hein, Rüdiger, MD</creatorcontrib><creatorcontrib>Ollert, Markus, MD</creatorcontrib><creatorcontrib>Mempel, Martin, MD</creatorcontrib><title>Low-dose anti-IgE therapy in patients with atopic eczema with high serum IgE levels</title><title>Journal of allergy and clinical immunology</title><addtitle>J Allergy Clin Immunol</addtitle><description>[...]the observed outcome in our omalizumab trial might not entirely reflect drug-associated clinical changes. [...]only a very small proportion (probably between 1% and 5 % of all serum IgE molecules) in our patients was bound by omalizumab.</description><subject>Adult</subject><subject>Allergy and Immunology</subject><subject>Anti-Allergic Agents - administration & dosage</subject><subject>Anti-Allergic Agents - pharmacology</subject><subject>Anti-Allergic Agents - therapeutic use</subject><subject>Antibodies, Anti-Idiotypic - administration & dosage</subject><subject>Antibodies, Anti-Idiotypic - therapeutic use</subject><subject>Antibodies, Monoclonal - administration & dosage</subject><subject>Antibodies, Monoclonal - pharmacology</subject><subject>Antibodies, Monoclonal - therapeutic use</subject><subject>Antibodies, Monoclonal, Humanized</subject><subject>Dermatitis, Atopic - drug therapy</subject><subject>Drug dosages</subject><subject>Eczema</subject><subject>Female</subject><subject>Humans</subject><subject>Immunoglobulin E - blood</subject><subject>Immunoglobulin E - drug effects</subject><subject>Immunoglobulin E - genetics</subject><subject>Immunoglobulins</subject><subject>Male</subject><subject>Middle Aged</subject><subject>Omalizumab</subject><subject>Patients</subject><subject>Treatment Outcome</subject><issn>0091-6749</issn><issn>1097-6825</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2007</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNp9kc1q3DAURkVpaaZpX6CLYih0Z_dKsiULSqGEtA0MdJFkLWTpTkau_yrZCZOnj8wMBLLoSkic7-PqXEI-UigoUPG1LVpjfcEAZAF1AQJekQ0FJXNRs-o12QAomgtZqjPyLsYW0p3X6i05o1JxUSu2Idfb8SF3Y8TMDLPPr-4us3mPwUyHzA_ZZGaPwxyzBz_vMzOPk7cZ2kfszfFp7-_2WcSw9Nka7fAeu_ievNmZLuKH03lObn9e3lz8zrd_fl1d_NjmtuRyztFy4eqSOWl4GpqDYFhTcJVkKJTgzu0aS6vG7CrOoTG8LI2sueWNomhT6Jx8OfZOYfy3YJx176PFrjMDjkvUoi6lUiVL4OcXYDsuYUizaVpBKaXgXCWKHSkbxhgD7vQUfG_CQVPQq3Dd6lW4XoVrqHUSnkKfTtVL06N7jpwMJ-DbEUhi8N5j0NEmpxadD2hn7Ub___7vL-K284O3pvuLB4zP_9CRadDX68rXjYNMhYIy_gRnDaT_</recordid><startdate>20071101</startdate><enddate>20071101</enddate><creator>Belloni, Benedetta, MD</creator><creator>Ziai, Mahzad, MD</creator><creator>Lim, Annick, MS</creator><creator>Lemercier, Brigitte, BS</creator><creator>Sbornik, Martin, MD</creator><creator>Weidinger, Stephan, MD</creator><creator>Andres, Christian, MD</creator><creator>Schnopp, Christina, MD</creator><creator>Ring, Johannes, MD</creator><creator>Hein, Rüdiger, MD</creator><creator>Ollert, Markus, MD</creator><creator>Mempel, Martin, MD</creator><general>Mosby, Inc</general><general>Elsevier Limited</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7SS</scope><scope>7T5</scope><scope>H94</scope><scope>K9.</scope><scope>NAPCQ</scope><scope>7X8</scope></search><sort><creationdate>20071101</creationdate><title>Low-dose anti-IgE therapy in patients with atopic eczema with high serum IgE levels</title><author>Belloni, Benedetta, MD ; Ziai, Mahzad, MD ; Lim, Annick, MS ; Lemercier, Brigitte, BS ; Sbornik, Martin, MD ; Weidinger, Stephan, MD ; Andres, Christian, MD ; Schnopp, Christina, MD ; Ring, Johannes, MD ; Hein, Rüdiger, MD ; Ollert, Markus, MD ; Mempel, Martin, MD</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c437t-ec36d842d7a30973062e810d572e6963ddfbc15baf5330ba344a783c3b91ec7a3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2007</creationdate><topic>Adult</topic><topic>Allergy and Immunology</topic><topic>Anti-Allergic Agents - administration & dosage</topic><topic>Anti-Allergic Agents - pharmacology</topic><topic>Anti-Allergic Agents - therapeutic use</topic><topic>Antibodies, Anti-Idiotypic - administration & dosage</topic><topic>Antibodies, Anti-Idiotypic - therapeutic use</topic><topic>Antibodies, Monoclonal - administration & dosage</topic><topic>Antibodies, Monoclonal - pharmacology</topic><topic>Antibodies, Monoclonal - therapeutic use</topic><topic>Antibodies, Monoclonal, Humanized</topic><topic>Dermatitis, Atopic - drug therapy</topic><topic>Drug dosages</topic><topic>Eczema</topic><topic>Female</topic><topic>Humans</topic><topic>Immunoglobulin E - blood</topic><topic>Immunoglobulin E - drug effects</topic><topic>Immunoglobulin E - genetics</topic><topic>Immunoglobulins</topic><topic>Male</topic><topic>Middle Aged</topic><topic>Omalizumab</topic><topic>Patients</topic><topic>Treatment Outcome</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Belloni, Benedetta, MD</creatorcontrib><creatorcontrib>Ziai, Mahzad, MD</creatorcontrib><creatorcontrib>Lim, Annick, MS</creatorcontrib><creatorcontrib>Lemercier, Brigitte, BS</creatorcontrib><creatorcontrib>Sbornik, Martin, MD</creatorcontrib><creatorcontrib>Weidinger, Stephan, MD</creatorcontrib><creatorcontrib>Andres, Christian, MD</creatorcontrib><creatorcontrib>Schnopp, Christina, MD</creatorcontrib><creatorcontrib>Ring, Johannes, MD</creatorcontrib><creatorcontrib>Hein, Rüdiger, MD</creatorcontrib><creatorcontrib>Ollert, Markus, MD</creatorcontrib><creatorcontrib>Mempel, Martin, MD</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Entomology Abstracts (Full archive)</collection><collection>Immunology Abstracts</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Nursing & Allied Health Premium</collection><collection>MEDLINE - Academic</collection><jtitle>Journal of allergy and clinical immunology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Belloni, Benedetta, MD</au><au>Ziai, Mahzad, MD</au><au>Lim, Annick, MS</au><au>Lemercier, Brigitte, BS</au><au>Sbornik, Martin, MD</au><au>Weidinger, Stephan, MD</au><au>Andres, Christian, MD</au><au>Schnopp, Christina, MD</au><au>Ring, Johannes, MD</au><au>Hein, Rüdiger, MD</au><au>Ollert, Markus, MD</au><au>Mempel, Martin, MD</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Low-dose anti-IgE therapy in patients with atopic eczema with high serum IgE levels</atitle><jtitle>Journal of allergy and clinical immunology</jtitle><addtitle>J Allergy Clin Immunol</addtitle><date>2007-11-01</date><risdate>2007</risdate><volume>120</volume><issue>5</issue><spage>1223</spage><epage>1225</epage><pages>1223-1225</pages><issn>0091-6749</issn><eissn>1097-6825</eissn><abstract>[...]the observed outcome in our omalizumab trial might not entirely reflect drug-associated clinical changes. [...]only a very small proportion (probably between 1% and 5 % of all serum IgE molecules) in our patients was bound by omalizumab.</abstract><cop>United States</cop><pub>Mosby, Inc</pub><pmid>17936892</pmid><doi>10.1016/j.jaci.2007.08.060</doi><tpages>3</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0091-6749 |
| ispartof | Journal of allergy and clinical immunology, 2007-11, Vol.120 (5), p.1223-1225 |
| issn | 0091-6749 1097-6825 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_68479942 |
| source | MEDLINE; Elsevier ScienceDirect Journals; Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals |
| subjects | Adult Allergy and Immunology Anti-Allergic Agents - administration & dosage Anti-Allergic Agents - pharmacology Anti-Allergic Agents - therapeutic use Antibodies, Anti-Idiotypic - administration & dosage Antibodies, Anti-Idiotypic - therapeutic use Antibodies, Monoclonal - administration & dosage Antibodies, Monoclonal - pharmacology Antibodies, Monoclonal - therapeutic use Antibodies, Monoclonal, Humanized Dermatitis, Atopic - drug therapy Drug dosages Eczema Female Humans Immunoglobulin E - blood Immunoglobulin E - drug effects Immunoglobulin E - genetics Immunoglobulins Male Middle Aged Omalizumab Patients Treatment Outcome |
| title | Low-dose anti-IgE therapy in patients with atopic eczema with high serum IgE levels |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-31T09%3A09%3A11IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Low-dose%20anti-IgE%20therapy%20in%20patients%20with%20atopic%20eczema%20with%20high%20serum%20IgE%20levels&rft.jtitle=Journal%20of%20allergy%20and%20clinical%20immunology&rft.au=Belloni,%20Benedetta,%20MD&rft.date=2007-11-01&rft.volume=120&rft.issue=5&rft.spage=1223&rft.epage=1225&rft.pages=1223-1225&rft.issn=0091-6749&rft.eissn=1097-6825&rft_id=info:doi/10.1016/j.jaci.2007.08.060&rft_dat=%3Cproquest_cross%3E68479942%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1504776339&rft_id=info:pmid/17936892&rft_els_id=1_s2_0_S0091674907016612&rfr_iscdi=true |